Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay
News Sep 13, 2017
Agilent Technologies has announced that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization (CGH) assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital irregularities, and unexplained dysmorphic features, earlier and more accurately than traditional methods.
The GenetiSure Dx Postnatal Assay is the result of an extensive clinical validation utilizing 900 samples from multiple partner laboratories and brings CGH technology into diagnostics. Based on Agilent's proprietary array for comparative genomic hybridization, this assay provides data on copy number variations and absence of heterozygosity in genomic DNA obtained from peripheral whole blood in patients who have been referred for chromosomal testing based on clinical presentation. The ability to detect both types of aberrations using a single assay provides greater diagnostic yield and faster time-to-results.
Previously available only in Europe, U.S. clinical genetic scientists can now use this assay to help identify a definitive genetic diagnosis, and rapidly change the focus of a medical investigation from finding the cause to administering appropriate medical care and family support.
"Obtaining FDA clearance of the GenetiSure Dx Postnatal Assay is a major milestone for us and solidifies Agilent’s commitment to bringing complete diagnostic solutions into routine clinical laboratories," said Kamni Vijay, vice president and general manager of Agilent’s Genomics Solutions Division and Clinical Applications Division. "By providing a validated workflow that extends from DNA to data analysis, this assay allows traditional karyotyping labs to easily adopt array-based cytogenetic testing without the high cost of extensive validation.”
This assay is intended for use on the Agilent SureScan Dx Microarray Scanner System, a Class II Exempt Medical Device, and analyzed with CytoDx Software.
This article has been republished from materials provided by Agilent Technologies. Note: material may have been edited for length and content. For further information, please contact the cited source.
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE
Drug Transport Gene May Explain Why Ovarian Cancer Patients React Differently to ChemotherapyNews
A gene which produces a protein that transports drugs in and out of cells may explain why some women treated with chemo have serious side effects.READ MORE